Teasing out the overall survival benefit with adjustment for treatment switching to other therapies

Yuqing Xu, Meijing Wu, Weili He +2

In oncology clinical trials, characterizing the long-term overall survival (OS) benefit for an experimental drug or treatment regimen (experimental group) is often unobservable if…